# Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

> **NCT07244393** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cellbion Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Lutetium (177Lu) DGUL
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07244393
- **Lead sponsor:** Cellbion Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07244393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07244393, "Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07244393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*